9.515
Precedente Chiudi:
$8.96
Aprire:
$8.9
Volume 24 ore:
76,937
Relative Volume:
0.52
Capitalizzazione di mercato:
$117.28M
Reddito:
$1.54M
Utile/perdita netta:
$-38.70M
Rapporto P/E:
-2.0375
EPS:
-4.67
Flusso di cassa netto:
$-36.86M
1 W Prestazione:
+4.45%
1M Prestazione:
+15.05%
6M Prestazione:
+0.37%
1 anno Prestazione:
-82.04%
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Nome
Corbus Pharmaceuticals Holdings Inc
Settore
Industria
Telefono
617-963-0103
Indirizzo
500 RIVER RIDGE DRIVE, NORWOOD, MA
Confronta CRBP con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
CRBP
Corbus Pharmaceuticals Holdings Inc
|
9.57 | 106.25M | 1.54M | -38.70M | -36.86M | -4.67 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
393.60 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
562.07 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
434.49 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
645.68 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
![]()
ONC
Beone Medicines Ltd Adr
|
303.40 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-07-30 | Ripresa | B. Riley Securities | Buy |
2025-02-28 | Iniziato | William Blair | Outperform |
2024-12-02 | Iniziato | Piper Sandler | Overweight |
2024-07-30 | Iniziato | Wedbush | Outperform |
2024-07-22 | Ripresa | H.C. Wainwright | Buy |
2024-06-26 | Iniziato | B. Riley Securities | Buy |
2024-06-03 | Reiterato | Oppenheimer | Outperform |
2024-05-13 | Iniziato | RBC Capital Mkts | Outperform |
2024-03-06 | Aggiornamento | Jefferies | Hold → Buy |
2020-09-08 | Downgrade | BTIG Research | Buy → Neutral |
2020-09-08 | Downgrade | Jefferies | Buy → Hold |
2020-09-08 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
2020-09-08 | Downgrade | ROTH Capital | Buy → Neutral |
2020-07-07 | Iniziato | ROTH Capital | Buy |
2020-06-17 | Iniziato | BTIG Research | Buy |
2020-03-26 | Iniziato | Nomura | Buy |
2019-04-05 | Iniziato | Jefferies | Buy |
2019-03-20 | Iniziato | Oppenheimer | Outperform |
2019-01-11 | Reiterato | Cantor Fitzgerald | Overweight |
2018-12-26 | Iniziato | H.C. Wainwright | Buy |
2018-12-07 | Iniziato | RBC Capital Mkts | Outperform |
2018-10-24 | Iniziato | B. Riley FBR | Buy |
2018-01-19 | Iniziato | Raymond James | Outperform |
2017-12-14 | Reiterato | Cantor Fitzgerald | Overweight |
2017-11-08 | Reiterato | Noble Financial | Buy |
2017-09-29 | Ripresa | Noble Financial | Buy |
2017-03-30 | Reiterato | Cantor Fitzgerald | Overweight |
2016-11-15 | Reiterato | JMP Securities | Mkt Outperform |
2016-11-11 | Reiterato | Noble Financial | Buy |
Mostra tutto
Corbus Pharmaceuticals Holdings Inc Borsa (CRBP) Ultime notizie
What is the next catalyst for Corbus Pharmaceuticals Holdings Inc.Free Trading Indicator Pack - thegnnews.com
Can Cannabis Stocks Reverse Their Prolonged Downtrend? - The Globe and Mail
Oppenheimer Lowers Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target to $53.00 - Defense World
Corbus Pharmaceuticals Reports Q2 2025 Financials and Updates - TipRanks
William Blair Issues Negative Outlook for CRBP Earnings - Defense World
Using flow based indicators on Corbus Pharmaceuticals Holdings Inc.Free Real Time Stock Movement Analysis - Newser
How moving averages guide Corbus Pharmaceuticals Holdings Inc. tradingSwing Candidate List with Trade Cues - Newser
Oppenheimer Maintains Outperform Rating for CRBP with Lowered Price Target of $53.00 - AInvest
Oppenheimer Maintains Outperform Rating for CRBP, Lowers Price T - GuruFocus
Corbus Pharmaceuticals: Q2 Earnings Snapshot - New Haven Register
Corbus (CRBP) Q2 Loss Beats Estimates - AOL.com
Key metrics from Corbus Pharmaceuticals Holdings Inc.’s quarterly dataSummary of Long-Term Buy Zone Stocks - Newser
Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewswire
Corbus Pharmaceuticals Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Corbus Pharmaceuticals Receives FDA Fast Track Designation - TipRanks
Corbus Pharmaceuticals Q2 basic eps usd -1.44 - MarketScreener
Corbus Pharmaceuticals (CRBP) Gears Up for Pivotal Data Presentations in Late 2025 - GuruFocus
Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update | CRBP Stock News - GuruFocus
Corbus Advances 3 Clinical Programs: Obesity Drug Trial Expands, Cancer Data Coming to ESMO - Stock Titan
Is Corbus Pharmaceuticals Holdings Inc. stock overvalued or undervaluedBuild wealth steadily with smart trading - Jammu Links News
Is Corbus Pharmaceuticals Holdings Inc. a growth stock or a value stockSkyrocketing investment returns - Jammu Links News
Is Corbus Pharmaceuticals Holdings Inc. a good long term investmentFree Stock Market Return Analysis - Jammu Links News
What is the risk reward ratio of investing in Corbus Pharmaceuticals Holdings Inc. stockGet timely alerts on market opportunities - Jammu Links News
Is it the right time to buy Corbus Pharmaceuticals Holdings Inc. stockExplosive portfolio gains - Jammu Links News
What are the latest earnings results for Corbus Pharmaceuticals Holdings Inc.Superior profit margins - Jammu Links News
When is Corbus Pharmaceuticals Holdings Inc. stock expected to show significant growthDiscover breakthrough stocks before the crowd - Jammu Links News
What analysts say about Corbus Pharmaceuticals Holdings Inc. stockInvest smarter with data-backed trading alerts - Jammu Links News
What are Corbus Pharmaceuticals Holdings Inc. company’s key revenue driversFree Stock Review Backed By Experts - Jammu Links News
What is B. Riley’s Forecast for CRBP Q2 Earnings? - Defense World
What is the dividend policy of Corbus Pharmaceuticals Holdings Inc. stockFinancial News Target Finder For Smart Trading - Jammu Links News
Why is Corbus Pharmaceuticals Holdings Inc. stock attracting strong analyst attentionReal Time Tracker For Fast Growth - Jammu Links News
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Recommendation of “Buy” by Brokerages - Defense World
Corbus Pharmaceuticals stock rises after ESMO abstract acceptance By Investing.com - Investing.com Australia
Dermatomyositis Treatment Market 2034: EMA, PDMA, FDA - openPR.com
Corbus Pharmaceuticals Announces Upcoming Presentation of - GlobeNewswire
Corbus to present updated CRB-701 cancer drug data at ESMO 2025 By Investing.com - Investing.com South Africa
Corbus to present updated CRB-701 cancer drug data at ESMO 2025 - Investing.com Nigeria
Corbus Pharmaceuticals stock rises after ESMO abstract acceptance - Investing.com
CRBP: B. Riley Maintains Buy Rating with Promising Drug Potential - GuruFocus
Corbus Pharmaceuticals (CRBP) to Present Phase 1/2 Study Data at ESMO 2025 - GuruFocus
Corbus Pharmaceuticals Announces Upcoming Presentation of Dose E - GuruFocus
Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 at the 2025 ESMO Annual Congress | CRBP Stock News - GuruFocus
Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 at the 2025 ESMO Annual Congress - GlobeNewswire
Latest Clinical Data: Corbus' Next-Gen Cancer Drug Targets Multiple Advanced TumorsESMO 2025 Preview - Stock Titan
Strategies to average down on Corbus Pharmaceuticals Holdings Inc.Real Time Growth Signal with Smart Setup - Newser
How to build a custom watchlist for Corbus Pharmaceuticals Holdings Inc.Buy Opportunity Forecast for Fast Traders - Newser
Has Corbus Pharmaceuticals Holdings Inc. Stock Ever Crashed Historical Volatility ReviewDaily Stock Market Swing Alerts Highlight Key Movers - metal.it
How Corbus Pharmaceuticals Holdings Inc. stock performs during market volatilityFree Wealth Building Stock Market Ideas - Newser
Corbus Pharmaceuticals Holdings Inc. Stocks Attracting Dip BuyersLow Capital High Return Stock Plans Reviewed - metal.it
Corbus Pharmaceuticals Holdings Inc Azioni (CRBP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Corbus Pharmaceuticals Holdings Inc Azioni (CRBP) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Altmeyer Anne | Director |
May 30 '25 |
Sale |
7.25 |
1,392 |
10,096 |
1,391 |
Smethurst Dominic | Chief Medical Officer |
Mar 06 '25 |
Sale |
6.78 |
6,393 |
43,330 |
70,807 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):